Clinicopathologic Features of Advanced Squamous NSCLC
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Research works printed but not linked: 85
- Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 · DOI · Paper page
- Villaruz, 2013, Personalizing therapy in advanced non-small cell lung cancer, Semin Respir Crit Care Med, 34, 822, 10.1055/s-0033-1358552 · DOI
- Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221 · DOI · Paper page
- Zugazagoitia, 2014, The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects, J Thorac Dis, 6, S526
- Oliver, 2015, Squamous non-small cell lung cancer as a distinct clinical entity, Am J Clin Oncol, 38, 220, 10.1097/COC.0b013e3182a0e850 · DOI
- Morgensztern, 2009, Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005, J Thorac Oncol, 4, 1524, 10.1097/JTO.0b013e3181ba3634 · DOI
- Cetin, 2011, Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program, Clin Epidemiol, 3, 139, 10.2147/CLEP.S17191 · DOI · Paper page
- Hirsch, 2008, The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review, J Thorac Oncol, 3, 1468, 10.1097/JTO.0b013e318189f551 · DOI · Paper page
- Scagliotti, 2010, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer, J Clin Oncol, 28, 1835, 10.1200/JCO.2009.26.1321 · DOI · Paper page
- Socinski, 2012, Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial, J Clin Oncol, 30, 2055, 10.1200/JCO.2011.39.5848 · DOI · Paper page
- Travis, 2015, The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, J Thorac Oncol, 10, 1243, 10.1097/JTO.0000000000000630 · DOI · Paper page
- Thunnissen, 2012, The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group, Lung Cancer, 76, 1, 10.1016/j.lungcan.2011.10.017 · DOI · Paper page
- Terry, 2010, Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples, Am J Surg Pathol, 34, 1805, 10.1097/PAS.0b013e3181f7dae3 · DOI · Paper page
- Hallack Neto, 2009, p63 protein expression in high risk diffuse large B-cell lymphoma, J Clin Pathol, 62, 77, 10.1136/jcp.2008.059519 · doi:10.1136/jcp.2008.059519
- Bishop, 2012, p40 (δNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma, Mod Pathol, 25, 405, 10.1038/modpathol.2011.173 · DOI · Paper page
- Loo, 2010, Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens, J Thorac Oncol, 5, 442, 10.1097/JTO.0b013e3181d40fac · DOI · Paper page
- Gruver, 2012, Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung, Arch Pathol Lab Med, 136, 1339, 10.5858/arpa.2011-0575-OA · doi:10.5858/arpa.2011-0575-oa
- Rosado-de-Christenson, 1994, Bronchogenic carcinoma: radiologic-pathologic correlation, Radiographics, 14, 429, 10.1148/radiographics.14.2.8190965 · doi:10.1148/radiographics.14.2.8190965
- Gill, 2010, Cavities in the lung in oncology patients: imaging overview and differential diagnoses, Applied Radiology, 39, 10, 10.37549/AR1757 · doi:10.37549/ar1757
- Nichols, 2012, Causes of death of patients with lung cancer, Arch Pathol Lab Med, 136, 1552, 10.5858/arpa.2011-0521-OA · DOI
- Wilson, 2012, Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study, Am J Respir Crit Care Med, 185, 85, 10.1164/rccm.201107-1223OC · DOI
- Ito, 2012, Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy, BMC Cancer, 12, 27, 10.1186/1471-2407-12-27 · DOI
- Dela Cruz, 2011, Lung cancer: epidemiology, etiology, and prevention, Clin Chest Med, 32, 605, 10.1016/j.ccm.2011.09.001 · DOI · Paper page
- Peto, 2000, Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies, BMJ, 321, 323, 10.1136/bmj.321.7257.323 · DOI · Paper page
- Duarte, 2008, The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients, Lung Cancer, 61, 244, 10.1016/j.lungcan.2007.12.008 · doi:10.1016/j.lungcan.2007.12.008
- Fox, 2004, The effect of smoking status on survival following radiation therapy for non-small cell lung cancer, Lung Cancer, 44, 287, 10.1016/j.lungcan.2003.11.012 · DOI
- Papi, 2004, COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma, Thorax, 59, 679, 10.1136/thx.2003.018291 · DOI · Paper page
- Radzikowska, 2002, Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases, Ann Oncol, 13, 1087, 10.1093/annonc/mdf187 · DOI · Paper page
- Carter, 2015, Smoking and mortality—beyond established causes, N Engl J Med, 372, 631, 10.1056/NEJMsa1407211 · DOI · Paper page
- Youlden, 2008, The International Epidemiology of Lung Cancer: geographical distribution and secular trends, J Thorac Oncol, 3, 819, 10.1097/JTO.0b013e31818020eb · DOI · Paper page
- Schroeder, 2010, Don't forget tobacco, N Engl J Med, 363, 201, 10.1056/NEJMp1003883 · DOI
- Moyer, 2014, Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 160, 330
- Pinsky, 2013, The National Lung Screening Trial: results stratified by demographics, smoking history and lung cancer histology, Cancer, 119, 3976, 10.1002/cncr.28326 · DOI · Paper page
- Frauenfelder, 2014, Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening, Respiration, 87, 254, 10.1159/000357049 · doi:10.1159/000357049
- Prosch, 2014, Screening for lung cancer, Curr Opin Oncol, 26, 131, 10.1097/CCO.0000000000000055 · DOI
- Devesa, 2005, International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising, Int J Cancer, 117, 294, 10.1002/ijc.21183 · DOI · Paper page
- Houston, 2014, Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009, Lung Cancer, 86, 22, 10.1016/j.lungcan.2014.08.001 · DOI · Paper page
- Sakurai, 2010, Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study, J Thorac Oncol, 5, 1594, 10.1097/JTO.0b013e3181f1923b · DOI
- Visbal, 2004, Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002, Ann Thorac Surg, 78, 209, 10.1016/j.athoracsur.2003.11.021 · DOI · Paper page
- Nadpara, 2015, Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States, J Geriatr Oncol, 6, 101, 10.1016/j.jgo.2015.01.001 · DOI
- Aarts, 2015, Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy, Int J Cancer, 136, E387, 10.1002/ijc.29216 · DOI
- Janssen-Heijnen, 1998, Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study, Lung Cancer, 21, 105, 10.1016/S0169-5002(98)00039-7 · DOI · Paper page
- Asmis, 2008, Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials, J Clin Oncol, 26, 54, 10.1200/JCO.2007.12.8322 · DOI · Paper page
- Jørgensen, 2012, Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality, Br J Cancer, 106, 1353, 10.1038/bjc.2012.46 · DOI · Paper page
- Lee, 2013, Indirectly estimated absolute lung cancer mortality rates by smoking status and histological type based on a systematic review, BMC Cancer, 13, 189, 10.1186/1471-2407-13-189 · DOI
- Søgaard, 2013, The impact of comorbidity on cancer survival: a review, Clin Epidemiol, 5, 3, 10.2147/CLEP.S47150 · DOI · Paper page
- Wang, 2014, Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry, J Exp Clin Cancer Res, 33, 109, 10.1186/s13046-014-0109-2 · doi:10.1186/s13046-014-0109-2
- Forbes, 2008, The Catalogue of Somatic Mutations in Cancer (COSMIC), Curr Protoc Hum Genet, 10.1002/0471142905.hg1011s57 · DOI · Paper page
- Caliò, 2014, ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung, J Thorac Oncol, 9, 729, 10.1097/JTO.0000000000000109 · DOI
- Rekhtman, 2012, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations, Clin Cancer Res, 18, 1167, 10.1158/1078-0432.CCR-11-2109 · DOI · Paper page
- Liao, 2012, Targeted therapy for squamous cell lung cancer, Lung Cancer Manag, 1, 293, 10.2217/lmt.12.40 · DOI
- Pao, 2011, New driver mutations in non-small-cell lung cancer, Lancet Oncol, 12, 175, 10.1016/S1470-2045(10)70087-5 · DOI · Paper page
- Kim, 2014, Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients, J Clin Oncol, 32, 121, 10.1200/JCO.2013.50.8556 · DOI · Paper page
- Hirsch, 2003, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis, J Clin Oncol, 21, 3798, 10.1200/JCO.2003.11.069 · DOI · Paper page
- Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 13, 33, 10.1016/S1470-2045(11)70318-7 · DOI · Paper page
- Thatcher, 2015, Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial, Lancet Oncol, 16, 763, 10.1016/S1470-2045(15)00021-2 · DOI · Paper page
- Pirker, 2012, Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study, Lung Cancer, 77, 376, 10.1016/j.lungcan.2012.03.010 · DOI
- Young, 2015, Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo, Target Oncol, 10, 501, 10.1007/s11523-014-0353-6 · DOI
- Dutt, 2011, Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer, PLoS One, 6, e20351, 10.1371/journal.pone.0020351 · DOI · Paper page
- Heist, 2012, FGFR1 amplification in squamous cell carcinoma of the lung, J Thorac Oncol, 7, 1775, 10.1097/JTO.0b013e31826aed28 · DOI · Paper page
- Gadgeel, 2013, Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR, PLoS One, 8, e79820, 10.1371/journal.pone.0079820 · DOI
- Sos, 2012, Genetic insight and therapeutic targets in squamous-cell lung cancer, Oncogene, 31, 4811, 10.1038/onc.2011.640 · DOI
- Weiss, 2010, Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer, Sci Transl Med, 2, 10.1126/scitranslmed.3001451 · DOI · Paper page
- Paik, 2014, A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumour activity and pharmacodynamic data [abstract], J Clin Oncol, 32, 8035, 10.1200/jco.2014.32.15_suppl.8035 · doi:10.1200/jco.2014.32.15_suppl.8035
- Nogova, 2014, Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398 [abstract], J Clin Oncol, 32, 8034, 10.1200/jco.2014.32.15_suppl.8034 · doi:10.1200/jco.2014.32.15_suppl.8034
- Wynes, 2014, FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies, Clin Cancer Res, 20, 3299, 10.1158/1078-0432.CCR-13-3060 · DOI
- Okudela, 2007, PIK3CA mutation and amplification in human lung cancer, Pathol Int, 57, 664, 10.1111/j.1440-1827.2007.02155.x · DOI · Paper page
- Heist, 2012, Genetic changes in squamous cell lung cancer: a review, J Thorac Oncol, 7, 924, 10.1097/JTO.0b013e31824cc334 · DOI · Paper page
- Vansteenkiste, 2015, Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study, J Thorac Oncol, 10, 1319, 10.1097/JTO.0000000000000607 · DOI · Paper page
- Hammerman, 2011, Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer, Cancer Discov, 1, 78, 10.1158/2159-8274.CD-11-0005 · DOI · Paper page
- Miao, 2014, Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients, BMC Cancer, 14, 369, 10.1186/1471-2407-14-369 · DOI
- Brunner, 2013, Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung, J Thorac Oncol, 8, 1434, 10.1097/JTO.0b013e3182a47162 · DOI
- Shibata, 2010, Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway, Cancer Res, 70, 9095, 10.1158/0008-5472.CAN-10-0384 · DOI · Paper page
- Kim, 2009, Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration, Lung, 187, 401, 10.1007/s00408-009-9181-3 · DOI
- Vansteenkiste J, Cho BC, Vanakesa T, et al. MAGRIT, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Abstract 1173O presented at the 2014 European Society Medical Oncology Congress. September 26–30, 2014; Madrid, Spain. · DOI
- Ikeda, 2006, Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinoma, Acta Cytol, 50, 423, 10.1159/000325986 · doi:10.1159/000325986
- Yoshida, 2006, Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance, Int J Oncol, 28, 1089
- da Costa Souza, 2012, Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma, Histopathology, 61, 587, 10.1111/j.1365-2559.2012.04318.x · DOI
- Kitazono, 2015, Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer, Clin Lung Cancer, 16, 385, 10.1016/j.cllc.2015.03.008 · DOI
- Velcheti, 2014, Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, 94, 107, 10.1038/labinvest.2013.130 · DOI · Paper page
- D'Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 112, 95, 10.1038/bjc.2014.555 · DOI · Paper page
- Rebelatto, 2015, Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients, J Clin Oncol, 3, 8033, 10.1200/jco.2015.33.15_suppl.8033 · DOI · Paper page
- Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
- Brahmer, 2015, KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1), J Clin Oncol, 33, TPS8103, 10.1200/jco.2015.33.15_suppl.tps8103 · doi:10.1200/jco.2015.33.15_suppl.tps8103
- Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 · DOI · Paper page
Cited by
Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.011 · Cited by 322
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
Self-citationXiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02722-3 · Cited by 173
Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0125-3 · Cited by 69
Zhang, X., Xiao, Q., Zhang, C., Zhou, Q., & Xu, T. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18262 · Cited by 14
“57 Immune inhibitors combined with chemotherapy have become a preferred option for LUSC treat - ment in recent years, although satisfactory results have not been achieved owing to the heterogeneity of the tumours.”
Background
Metadata
- Authors
- Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Pérol, M., Reck, M., Ramalingam, S. S., Reynolds, C. H., Spigel, D. R., Stinchcombe, T. E., Wakelee, H., Mayo, C., & Thatcher, N.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 11
- Issue
- 9
- Pages
- 1411-1422
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2416190981
- Cited by
- 180
- References
- 16
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.